Abstract：
BACKGROUND: Acute tubulointerstitial nephritis (ATIN) is a well-recognized cause of acute kidney injury (AKI) due to the tubulointerstitial inflammation. The aim of this study was to explore the clinical features, outcomes, and responses to corticosteroid treatment in patients with ATIN.
METHODS: Patients with biopsy-proven ATIN, who were diagnosed between 1994 and 2016 at the Department of Nephrology, Charles University, First Faculty of Medicine, and General University Hospital in Prague, were included in the study. Patient demographics, the aetiological and clinical features, the treatment given, and the outcome at 1 year of follow-up were extracted from patient records.
RESULTS: A total of 103 ATIN patients were analysed, of which 68 had been treated with corticosteroids. There was no significant difference in the median serum creatinine 280 (169-569) µmol/L in the conservatively managed group versus 374 (249-558) µmol/L in the corticosteroid-treated group, p = 0.18, and dependence on dialysis treatment at baseline at the time of biopsy (10.3 vs. 8.6%). During the 1 year of follow-up, those ATIN patients who had been treated with corticosteroids did better and showed greater improvement in kidney function, determined as serum creatinine difference from baseline and from 1 month over 1-year period (p = 0.001).
CONCLUSIONS: This single-centre retrospective cohort study supports the beneficial role of the administration of corticosteroid therapy in the management of ATIN.
METHODS: Patients with biopsy-proven ATIN, who were diagnosed between 1994 and 2016 at the Department of Nephrology, Charles University, First Faculty of Medicine, and General University Hospital in Prague, were included in the study. Patient demographics, the aetiological and clinical features, the treatment given, and the outcome at 1 year of follow-up were extracted from patient records.
RESULTS: A total of 103 ATIN patients were analysed, of which 68 had been treated with corticosteroids. There was no significant difference in the median serum creatinine 280 (169-569) µmol/L in the conservatively managed group versus 374 (249-558) µmol/L in the corticosteroid-treated group, p = 0.18, and dependence on dialysis treatment at baseline at the time of biopsy (10.3 vs. 8.6%). During the 1 year of follow-up, those ATIN patients who had been treated with corticosteroids did better and showed greater improvement in kidney function, determined as serum creatinine difference from baseline and from 1 month over 1-year period (p = 0.001).
CONCLUSIONS: This single-centre retrospective cohort study supports the beneficial role of the administration of corticosteroid therapy in the management of ATIN.
摘要：
背景：急性肾小管间质性肾炎（ATIN）是由于肾小管间质性炎症引起的急性肾损伤（AKI）的公认原因。这项研究的目的是探讨临床特征，结果，ATIN患者对皮质类固醇治疗的反应。
方法：活检证实ATIN的患者，他们在1994-2016年间在肾脏科被诊断出，查尔斯大学,布拉格第一医学院和普通大学医院，包括在研究中。患者人口统计学，病因和临床特征，给予的治疗，并从患者记录中提取随访一年时的结局.
结果：共分析了103名ATIN患者，其中68人接受过皮质类固醇治疗。保守治疗组与保守治疗组的中位血清肌酐280（169-569）µmol/l没有显着差异。在皮质类固醇治疗组中374（249-558）µmol/l，p=0.18，活检时基线时对透析治疗的依赖性（10.3％vs8.6％）。在一年的随访中，那些接受过皮质类固醇治疗的ATIN患者表现更好，肾功能改善更大，确定为血清肌酐与基线和一年内一个月的差异（p=0.001）。
结论：这项单中心回顾性队列研究支持皮质类固醇治疗在ATIN治疗中的有益作用。
方法：活检证实ATIN的患者，他们在1994-2016年间在肾脏科被诊断出，查尔斯大学,布拉格第一医学院和普通大学医院，包括在研究中。患者人口统计学，病因和临床特征，给予的治疗，并从患者记录中提取随访一年时的结局.
结果：共分析了103名ATIN患者，其中68人接受过皮质类固醇治疗。保守治疗组与保守治疗组的中位血清肌酐280（169-569）µmol/l没有显着差异。在皮质类固醇治疗组中374（249-558）µmol/l，p=0.18，活检时基线时对透析治疗的依赖性（10.3％vs8.6％）。在一年的随访中，那些接受过皮质类固醇治疗的ATIN患者表现更好，肾功能改善更大，确定为血清肌酐与基线和一年内一个月的差异（p=0.001）。
结论：这项单中心回顾性队列研究支持皮质类固醇治疗在ATIN治疗中的有益作用。
